Oncological efficacy of adjuvant therapy in patients with localized clear cell renal carcinoma compared to standard therapy: a scoping review

Oncological efficacy of adjuvant therapy in patients with localized clear cell renal carcinoma compared to standard therapy: a scoping review

David A. Castañeda-Millán 1, 2, 3 , Diego R. Puentes-Montenegro 4 , María F. Mariño-Gómez 5 , Diego Camacho-Nieto 6

1 Unidad de Urología, Departamento de Cirugía, Facultad de Medicina, Universidad Nacional de Colombia, ogotá, Colombia; 2 Grupo de Investigación e Innovación en Urología, Facultad de Medicina, Universidad Nacional de Colombia, ogotá, Colombia; 3 Oficina de Investigación, Sociedad Colombiana de Urología, Bogotá, Colombia; 4 Instituto de Investigaciones Clínicas, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia; 5 Facultad de Medicina, Colegio Mayor Nuestra Señora del Rosario, Bogotá, Colombia; 6 Unidad de Urología Oncológica, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia

*Correspondence: David A. Castañeda-Millán. Email: dacastanedam@unal.edu.co

Abstract

Objective: Renal cancer (RC) is one of the genitourinary tumors with the highest incidence and prevalence worldwide. The treatment of metastatic stages has seen significant advancements due to the advent of systemic therapies. However, the clinical utility of such therapies in localized disease is not well known.

Method: A scoping review was conducted to define the oncological efficacy of adjuvant therapy (immunotherapy or tyrosine kinase inhibitors) in patients with localized clear cell RC with intermediate or high risk of recurrence compared to standard therapy.

Results: A total of 34 articles were identified, of which 12 were included for analysis, all of them randomized clinical trials.

Conclusions: Currently, there is no high-certainty evidence regarding the superiority of adjuvant strategies in the long term for all patients with localized clear cell RCC compared to the standard of care. However, the results obtained in high-risk RC patients with pembrolizumab in medium-term follow-up are promising.

Keywords: Carcinoma renal cell; Nephrectomy; Immunotherapy; Immune checkpoint inhibitors; Sunitinib; Tyrosine kinase inhibitors

Contents

English version not available. Please check the Spanish version.

⇄ Versión en Español
DOI: 10.24875/RUC.24000076
Add to Mendeley

Text only available in Spanish.

    PERMANYER

    Mallorca, 310
    08037 Barcelona (España)

    Arquímedes, 190 – Colonia Polanco
    Delegación Miguel Hidalgo
    11560 Ciudad de México (México)

    RECURRING LINKS
    CLOCKSS is a dak archive that ensures the long-term survival of web-based scholary publications, governed by and for its stakeholders.

    This journal adheres to the principles established by the Committee on Publication Ethics

    Descargar PDF
    English versión
    DOI: 10.24875/RUC.24000076

    Editorial times

    The editorial process consists of 6 stages:

    1. Reception of the manuscript (indeterminate, depending on whether the author meets the requirements): its objective is to verify that the manuscript complies with the specifications of these instructions for authors and that the submitted documentation is complete.

    2. Initial editorial review (maximum 5 business days): its objective is to corroborate the relevance, timeliness, originality, and scientific contribution of the manuscript, as well as the methodological and statistical soundness of the study. At this time, it will be submitted to an electronic plagiarism detection system. Derived from this, a rejected opinion may be obtained, or it will be sent for review by peer researchers.

    3. Review by peer researchers (maximum 30 business days): the opinion of at least two experts in the area in question will be obtained, who will evaluate the technical and methodological aspects of the investigation.

    4. Editorial review (maximum 7 business days): its objective is to make a decision based on the opinion of peer reviewers. The opinion can be rejected, major changes, minor changes or accepted. In the case of major or minor changes, it will be submitted again for evaluation by the initial peer reviewers.

    5. Final edition (6 weeks): its objective is the technical and linguistic edition (and translation), layout of galleys, DOI assignment, and correction by the author.

    6. Advanced publication: All manuscripts will be published ahead of print on the journal’s website as soon as they complete the editing process, until they are incorporated into a final issue of the journal.